Company intelligence / Profile preview

Brighthaven Ventures LLC

Raleigh, North Carolina, United States

Ownership: Private
Development stage: Other

Overview

Developed remogliflozin etabonate, an SGLT2 inhibitor that showed >1% HbA1c reduction in phase 2b trials for type 2 diabetes with low genitourinary infection rates; licensed to Islet Sciences in 2015, but deal effectiveness depended on funding that was not met amid disputes.

Therapeutic areas: EndocrinologyGastroenterology
Modalities: Small molecule
Industry: Biotech

Partnerships

Kissei Pharmaceuticals (licensor for remogliflozin)Islet Sciences, Inc. (licensee)

Beyond the preview

Go deeper on Brighthaven Ventures LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Brighthaven Ventures LLC.

Explore the full profile